Additionally, the authors assessed if approved drugs for other diseases might be linked to RA risk genes for drug repurposing and found, for instance, the cases of CDK4 and CDK6, which are targets for different types of cancer treatment [15] and have been shown to weaken disease activity in animal models of RA [15]. The gene discussed is CDK6; the disease is rheumatoid arthritis.